Literature DB >> 8575492

The role of adjuvant treatment in low-stage germ cell testicular tumors.

G Pizzocaro1, R Salvioni, N Nicolai.   

Abstract

OBJECTIVE: To find out up-to-date indications to adjuvant therapy in low-stage germ cell tumors (GCT) of the testis.
METHODS: The authors reviewed the material of the National Cancer Institute in Milan and the major international papers on adjuvant therapies of GCT of the testis.
RESULTS: Moderate dose irradiation of retroperitoneal nodes remains the standard therapy of stage I seminoma; mediastinal irradiation has been abandoned in stage II seminoma. Nerve-sparing retroperitoneal lymph node dissection and surveillance remain standard therapies for nonseminomatous stage I tumors; 2 adjuvant courses of cisplatin-based chemotherapy are under investigation in high-risk patients. Postoperative adjuvant chemotherapy is mandatory only in bulky pathological stage II non-seminoma, but it is advisable also in patients who cannot be carefully followed.
CONCLUSION: The cure rates of GCT of the testis can approach 100% in low stages and similar results can be achieved with different treatment modalities, but the maximum results can be obtained in specialized centers only.

Entities:  

Mesh:

Year:  1995        PMID: 8575492     DOI: 10.1159/000475066

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  1 in total

1.  External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer.

Authors:  Cédric Vallier; Pierre-Henri Savoie; Jean-Robert Delpero; Franck Bladou; Gwenaëlle Gravis; Naji Salem; Dominique Rossi; Jochen Walz
Journal:  World J Urol       Date:  2014-01-20       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.